BENEVOLENTAI DRUG PIPELINE

Atopic Dermatitis

DERMATOLOGY

Advancing a potent and selective Atopic Dermatitis treatment through the clinic

What is Atopic Dermatitis?

Atopic Dermatitis (AD), the most common type of eczema, is a chronic relapsing inflammatory skin disease that results in itchy, red, swollen, and cracked skin.

Our work

BEN-2293, a Pan-Trk antagonist, is being developed to treat AD without the need to use topical steroids and designed to address the debilitating itch and inflammation in both adults and children.

Progress so far

We are currently studying BEN-2293 in a Phase I/II proof-of-concept, randomised, first-in-human clinical trial in adult patients with mild to moderate disease.

Affects 10-20% of children and up to 3% of adults.(1)

Mild to moderate AD affects approximately 70% of all patients.(2)

Global prevalence is rising.

89% of patients reported limited treatment effectiveness and/or harm with their current treatment options.(3)

Our work

BEN-2293: Pan-Trk inhibitor for Atopic Dermatitis

Atopic Dermatitis is common worldwide and affects people of all ages, from newborns to adults 65 years of age and older. The condition is long lasting and tends to flare periodically, with symptoms ranging from excessively dry, itchy skin to painful, itchy rashes that cause sleepless nights, low self-esteem and interfere with everyday life.  It can be a difficult disease to endure as the current standard of care topical treatments (applied directly to the skin) include corticosteroids and calcineurin inhibitors which are both associated with significant safety risks with long term use.

There is an urgent unmet need for an effective and safe alternative topical therapy for the broad patient population. To meet this need, we designed and developed a novel small-molecule treatment, BEN-2293, to address the debilitating itch and inflammation in both adults and children.

BEN-2293 is a first-in-class, selective, highly potent small-molecule Pan-Trk antagonist. It is formulated to be administered topically, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in treating itch and inflammation from AD. BEN-2293 is currently being studied in a Phase I/II proof-of-concept, randomised, first-in-human clinical trial in adult patients with mild to moderate disease.

What's next

"This is an exciting time for BenevolentAI and as we evaluate the safety and efficacy of this drug, we are hoping to see results that could significantly improve the quality of life for children and adults suffering from this disease."

Jane McGuffog  —  Director Drug Discovery, BenevolentAI
References

(1) Atopic Dermatitis: Epidemiology Forecast to 2027 - GlobalData Report Store, 2021. [Accessed March 2021]

(2) Atopic Dermatitis: Epidemiology Forecast to 2027 - GlobalData Report Store, 2021. [Accessed March 2021]

(3) McCleary et al. More Than Skin Deep “Voice of the Patient”. Report, 2020. Available from: https://www.aafa.org/media/2628/more-than-skin-deep-voice-of-the-patient-report.pdf. [Accessed April 2021].